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Introduction
Infections with resistant organisms represent a serious menace
in critically ill patients. As options for effective chemotherapy
diminish, intensive care unit (ICU) mortality will increase. Mortal-
ity rates as high as 60% have been reported for serious infec-
tions (ventilator-associated pneumonia [VAP], bloodstream
infections) with inappropriate initial treatment [1–6]. In a recent
study [7], inadequate antimicrobial treatment of infection was an
important and independent determinant of mortality in critically ill
patients. In that series patients receiving inadequate treatment
had an in-hospital mortality rate of 52.1%, as compared with
12.2% in those patients who were adequately treated.
APACHE = Acute Physiology and Chronic Health Evaluation; CVVHD = continuous venovenous hemodiafiltration; ICU = intensive care unit; VAP =
ventilator-associated pneumonia.
Abstract
Introduction The increasing prevalence of multiresistant Gram-negative strains in intensive care units
(ICUs) has recently rekindled interest in colistin, a bactericidal antibiotic that was used in the 1960s for
treatment of infections caused by Gram-negative bacilli. We conducted the present observational
study to evaluate the efficacy of intravenous colistin in the treatment of critically ill patients with sepsis
caused by Gram-negative bacilli resistant to all other antibiotics.
Patients and method Critically ill patients with sepsis caused by Gram-negative bacilli resistant to all
antibiotics with the exception of colistin were treated in the six-bed ICU of a trauma hospital. Diagnosis
of infection was based on clinical data and isolation of bacteria, and the bacteria were tested with
respect to their susceptibility to colistin. Clinical response to colistin was evaluated.
Results Twenty-four patients (mean age 44.3 years, mean Acute Physiology and Chronic Health
Evaluation II score 20.6) received 26 courses of colistin. Clinical response was observed for 73% of
the treatments. Survival at 30 days was 57.7%. Deterioration in renal function was observed in 14.3%
of 21 patients who were not already receiving renal replacement therapy, but in only one case did this
deterioration have serious clinical consequences.
Conclusion The lack of a control group in the present study does not allow any definite conclusions to
be drawn regarding the clinical effectiveness of colistin. On the other hand, this drug has an
acceptable safety profile and its use should be considered in severe infections with multiresistant
Gram-negative bacilli.
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The increasing prevalence of multiresistant Gram-negative
strains in ICUs has recently rekindled interest in colistin
[8–12], a bactericidal antibiotic that was used in the 1960s
for treatment of infections caused by Gram-negative bacilli. A
high incidence of adverse effects (nephrotoxicity, neurotoxic-
ity), along with the development of newer effective drugs with
better safety profiles, resulted in the practical abandonment
of systemic use of colistin, although it still remains active in
vitro against practically all strains of Pseudomonas aerugi-
nosa and Acinetobacter spp. The presence of multiresistant
P. aeruginosa and  Acinetobacter baumannii strains in our
ICU prompted us to try treatment with colistin as a last resort
in patients with serious infections with such strains. Here we
report 3 years of experience with intravenous colistin in the
treatment of Gram-negative sepsis.
Patients and method
We studied critically ill patients with sepsis caused by Gram-
negative bacilli resistant to all antibiotics with the exception of
colistin. The patients were treated in a six-bed ICU in a
trauma hospital.
Diagnosis of infection was based on clinical data and the iso-
lation of bacteria, either from a normally sterile site or from
quantitative cultures of tracheal aspirate or bronchoalveolar
lavage. More specifically, the clinical prerequisites for the
diagnosis of VAP were as follows: presence of at least two of
fever (>38.3°C), leukocytosis or leukopenia, and purulent
bronchial secretions; and a new and persistent infiltrate on
chest radiography. On isolation of strains of P. aeruginosa
and A. baumannii that were resistant to all antibiotics apart
from colistin, intravenous colistin sulfomethate sodium (Col-
istin; Norma, Athens, Greece) was initiated at the discretion
of the attending physician. The dosage of colistin, adminis-
tered intravenously, was 3MU three times daily, adjusted for
creatinine clearance [10].
Susceptibility testing was done using an automated broth
microdilution test (Vitek; bioMérieux, Durham, NC, USA). The
breakpoints for susceptibility were those recommended by
the National Committee for Clinical Laboratory Standards.
Susceptibility to colistin was tested using the disk diffusion
method, with a 10µg colistin disk (Oxoid Ltd, Basingstoke,
Hants, UK). Isolated bacilli were considered susceptible if the
inhibition zone was 11mm or greater.
Results
In all, 28 patients were treated with colistin. In 16 cases col-
istin was part of the initial empiric regimen based on previous
surveillance cultures, with subsequent cultures confirming the
sensitivity pattern. For the remaining patients, colistin was
introduced when culture results became available in those
who had not responded to the initial empiric regimen. Four of
the 28 patients died within 48 hours of the initiation of colistin;
these patients were not included in the analysis because they
were not considered true therapeutic failures. Data on the
remaining 24 patients are presented in Table 1. The mean age
of the patients was 44.3 years and the mean Acute Physiology
and Chronic Health Evaluation (APACHE) II score was 20.6.
In five patients multiple organ failure was present at the initia-
tion of colistin. A total of 26 courses of colistin were given, for
the following infections: VAP (15 cases), empyema thoracis
(one case), post-traumatic meningitis (one case), sinusitis (one
case), urinary tract infection (one case), catheter-related
sepsis (three cases), and sepsis of unknown primary origin
(four cases). The offending pathogen was P. aeruginosa in
20 cases and A. baumannii in six. In six cases a co-pathogen
was isolated. Median duration of treatment with colistin was
13.5 days (range 4–24 days). In all cases a second antibiotic
(ceftazidime in 16, piperacillin/tazobactam in six, and a car-
bapenem in four cases) was added to the therapeutic
regimen, despite documented resistance.
Clinical response, judged as abatement of fever for at least
48 hours with parallel improvement in vital signs, was
observed for 17 of the 26 treatments. In two patients with
septic shock (one hypothermic and the other with low-grade
fever) it was possible to stop vasopressors in the following
48 hours, and this was also considered proof of response.
Thus, clinical response was seen for 19 out of 26 treatments
with colistin (73%). Survival at 30 days was 57.7%.
In the subgroup of patients with bacteremia (11 patients), an
initial clinical response to colistin was observed in seven
patients and the ICU mortality was 54.5%. Additional blood
culture data after initiation of colistin were available in two of
the clinical responders, and bacterial eradication was con-
firmed in both. In the subgroup of patients with VAP, 11 out
of 15 patients (73.3%) had an initial clinical response to col-
istin, bacterial eradication was observed in eight (53.3%),
and ICU mortality was 40%.
Three patients had already developed acute renal failure at
the initiation of treatment with colistin and were being treated
with continuous venovenous hemodiafiltration (CVVHD).
None of them survived. The other patients had a serum creati-
nine below 2.5mg/dl with one exception (a patient with
serum creatinine 3.2mg/dl), and all had adequate diuresis.
Only patients 8, 17 and 24 (14.3%) had an increase in serum
creatinine of greater than 1mg/dl during treatment, with no
serious consequences in patients 8 and 17. Only patient 24
developed anuria and serious impairment in renal function
requiring CVVHD (Table 2).
No patient developed clinically apparent neuromuscular
transmission blockade.
Discussion
Colistin is a cationic polypeptide antibiotic of the polymyxin
family that is rapidly bactericidal to Gram-negative bacteria.
The action of colistin is by a detergent-like mechanism, inter-
fering with the structure and function of the outer cytoplasmicR80
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membrane of bacteria and resulting in bacterial death
[11,13]. It is administered as colistin sulfomethate sodium
and its hydrolysis releases the active drug. It is removed by
glomerular filtration [10].
Colistin remains active in vitro against almost all strains of
P. aeruginosa,  Klebsiella pneumoniae,  Acinetobacter spp.,
and Enterobacter spp. On the other hand, Proteus spp., Prov-
idencia spp., Serratia spp., Burkholderia cepacia, and some
Table 1
Critically ill patients treated with colistin: clinical characteristics and outcome
Age APACHE II
Patient (years) Sex score Underlying disease Infection Pathogen Response, outcome
1 34 M 21 Trauma, ARDS VAP P. aeruginosa Initial response, Death
2 22 M 17 Trauma VAP P. aeruginosa Response
3 27 M 14 Trauma VAP P. aeruginosa Response
4 36 F 23 Burns, MOF (three organs) VAP P. aeruginosa No response, death
5 25 F 22 Trauma, ARDS VAP P. aeruginosa No response, death
6 47 M 13 Trauma VAP P. aeruginosa Response
7 64 M 17 Trauma VAP P. aeruginosa Response
8 52 F 16 Trauma VAP P. aeruginosa Response
9 29 M 26 Pancreatitis, MOF VAP P. aeruginosa Initial response, death
(three organs)
10 38 M 14 Subarachnoid hemorrhage VAP P. aeruginosa Response
11 66 M 28 Head and neck cancer, VAP P. aeruginosa No response, death
surgery, MOF (three organs)
12 34 F 16 Trauma VAP Acinetobacter spp. Response
13 80 M 21 Sternotomy, ARDS VAP Acinetobacter spp. Response
14 43 M 19 Trauma VAP Acinetobacter spp. Response
15 28 F 24 Morbid obesity, VAP Acinetobacter spp. No response, death
bowel resection




17 61 M 20 Trauma Catheter-related P. aeruginosa Response
sepsis
18 35 M 14 Trauma Catheter-related P. aeruginosa Response
sepsis
19 62 M 29 Trauma, MOF Catheter -related P. aeruginosa No response, death
(two organs), CVVHD sepsis
20 64 F 28 Burns, MOF Sepsis of unknown P. aeruginosa No response, death
(two organs), CVVHD primary origin
21 73 M 32 Cancer of the colon, Sepsis of unknown
bowel resection, MOF primary origin P. aeruginosa Initial response, death
(four organs)
22 29 M 14 Trauma Sepsis of unknown P. aeruginosa Response
primary origin
23 20 M 22 Trauma, crush syndrome, Empyema thoracis P. aeruginosa No response, death
CVVHD
24 74 M 28 Aneurysm of the abdominal Sepsis of unknown Acinetobacter spp. Initial response, death
aorta, elective operation primary origin
F, female; M, male; MOF, multiple organ failure; CVVHD, continuous venovenous hemodiafiltration.R81
strains of Stenotrophomonas maltophilia are usually resistant
to colistin [8–18]. Cross-resistance with other antibiotics has
not been reported [10,13], and acquired resistance is rare
[11,17]. Although lower susceptibility rates for P. aeruginosa
have been reported in patients with cystic fibrosis undergoing
chronic prophylactic treatment with inhaled colistin [18], 81%
of strains of P. aeruginosa from such patients are still suscep-
tible to colistin [14].
With regard to clinical efficacy, data are limited. In the 1960s
the drug, administered mostly via the intramuscular route, was
found to be of use in the treatment of infections with Gram-
negative bacteria resistant to other antibiotics. Response was
better in patients with bloodstream infections resulting from
urinary tract infection. Colistin was less effective in patients
with osteomyelitis, biliary tract disease, endocarditis, and sup-
purative infections of the lung (probably because of subopti-
mal concentrations locally), and it was ineffective in the
treatment of Gram-negative infections in neutropenic patients
[10,11,13].
In recent years intravenous colistin has occasionally been
used in acute exacerbations of multiresistant P. aeruginosa in
patients with cystic fibrosis [19–21]. With regard to adult
patients without cystic fibrosis treated with colistin, an obser-
vational study [9] reported a clinical response rate of 58%. In
that study the drug was used in 59 patients with serious
infections with A. baumannii (65%) and P. aeruginosa (35%)
resistant to all other antibiotics. Of the patients studied, 65%
were critically ill and the mean APACHE II score was 13.1.
Response was suboptimal (25%) in patients with pneumonia.
Recently, Garnacho-Montero and coworkers [12] reported
the only controlled study of colistin in patients without cystic
fibrosis. Patients with VAP caused by A. baumannii were
treated with imipenem (21 patients) or, in the case of resis-
tance to all other antibiotics, with colistin (14 patients).
APACHE II scores at presentation and Sequential Organ
Failure Assessment scores at the time of diagnosis of VAP
were similar between the groups. Achieving clinical cure in
57% of cases, intravenous colistin was as effective as
imipenem. No significant difference was observed between
the two groups in terms of crude mortality, VAP attributed
mortality, microbiologic cure, or duration of ICU stay. Limita-
tions of that study are the small number of patients included,
open design, and lack of randomization.
Clinical response in the present study was somewhat better
than in the study conducted by Levin and coworkers [9],
despite a higher mean APACHE II score. The observed
30-day mortality rate of 42.3% in the present study is cer-
tainly high but not unexpectedly so for the severity of illness.
Because mortality rates in the region of 50–60% have been
reported in critically ill patients receiving inappropriate treat-
ment [1–7], the use of colistin may indeed have been of clini-
cal benefit in our patients.
Both the study by Levin and coworkers [9] and a study of an
experimental pneumonia model with Acinetobacter sp. in
immunocompetent mice [22] suggest that, despite good in
vitro activity, the clinical efficacy of colistin may be suboptimal
in Gram-negative pneumonia. On the other hand, Garnacho-
Montero and coworkers [12] reported that colistin was not
inferior to the standard treatment for VAP caused by A. bau-
mannii, with a clinical cure rate of 57%. Results were rather
better in our patients with VAP, in whom a clinical response
was seen in 73.3% and bacterial eradication in 53.3%.
Perhaps the high doses of colistin used in our study were in
part responsible for this.
The dosage of colistin used in our study was more than
double that usually recommended [9,10,12], although much
higher doses – with a parallel increase in nephrotoxicity –
have been reported in the past [23]. We opted for the higher
dose because of the severity of the infections being treated.
A recent study that reported that colistin methanosulfate is
less rapidly bactericidal than is colistin in P. aeruginosa [14]
offers retrospective justification for the higher dosage used in
our ICU. It appears that peak concentrations of colistin
methanosulfate 16 times the minimum inhibitory concentra-
tion or greater are required for complete in vitro killing of
P. aeruginosa within 24 hours [14].
In the present study all patients received a β-lactam in addi-
tion to colistin, despite documented resistance. In some
Available online http://ccforum.com/content/7/5/R78
Table 2
Characteristics of patients with impairment in renal function after initiation of colistin
Serum creatinine (mg/dl)
Patient Characteristics Cr1 Cr2 Cr3
8 Age 52 years, female, trauma, VAP, septic shock 0.9 2.1 1.4
17 Age 61 years, male, trauma, catheter-related sepsis, diabetes mellitus 1.1 2.3 1.5
24 Age 74 years, male, aneurysm of the abdominal aorta, elective operation. 2.4 5.1 CVVHD, death
Sepsis of unknown primary origin, previous myocardial infarction, hypertension
Cr1, serum creatinine at initiation of colistin; Cr2, highest value of creatinine during treatment with colistin; Cr3, serum creatinine 7 days after
completion of treatment with colistin; CVVHD, continuous venovenous hemodiafiltration; VAP, ventilator-associated pneumonia.R82
cases the second drug was added to act against isolated co-
pathogens, but in most patients this addition indicated the
attending physician’s lack of confidence in monotherapy with
colistin. Although combinations of colistin with β-lactams are
reported to be of unproven benefit [24,25], a recent study
conducted in an in vitro pharmacodynamic model [28]
reported synergy with ceftazidime for P. aeruginosa sensitive
to colistin but resistant to other antibiotics, including cef-
tazidime. Synergy with colistin has been reported for
trimethoprim–sulfamathoxazole (co-trimoxazole) [27] and
rifampicin [26], but no patient in our study received these
antibiotics.
A possible drawback of the present study is the use of the
disk diffusion method for testing in vitro susceptibility to col-
istin. According to a recent study [15], this approach some-
times yields falsely susceptible results. However, because
errors are observed mainly for S. maltophilia and much less
often for Acinetobacter spp., it appears unlikely that the use
of a different method of susceptibility testing would materially
influence our findings.
Toxicity, particularly nephrotoxicity, is an important concern
with colistin. In the study conducted by Koch-Weser and
coworkers [29], impairment in renal function – usually
reversible with termination of treatment – was observed in
20.2% of 288 patients. Levin and coworkers [9] also
reported a high incidence of nephrotoxicity (37%), especially
in patients who already had compromised renal function [9].
Because most of the patients in both studies were seriously
ill, it is highly probable that at least part of the reported toxic-
ity was the result not of the drug but of the disease. On the
other hand, experience with the drug in patients with cystic
fibrosis, has shown only minimal nephrotoxicity [19–21,30].
Garnacho-Montero and coworkers [12], in patients with VAP,
observed that there was no significant difference in develop-
ment of renal failure between colistin and imipenem. In our
study, despite a dosage of colistin that was much higher than
that usually reported, nephrotoxicity was moderate (14.3%)
and it is unlikely that this had a clinically significant impact in
most cases, although the drug might have contributed to the
poor outcome of patients under CVVHD.
Neurotoxicity and neuromuscular blockade were also
reported with colistin in the 1960s [29,31], but more recent
studies did not report clinically evident [9,30] or neurophysio-
logic [12] abnormalities. No clinical neurotoxicity was
observed in the present study.
Conclusion
Although our findings with colistin can be considered encour-
aging in comparison with previous experience, the small
number of patients, the concomitant use of β-lactams, and
the absence of a control group in the study do not allow for a
clear verdict on the clinical effectiveness of colistin. On the
other hand, the moderate incidence of complications sug-
gests that colistin may be a relatively safe choice in patients
with normal renal function, at least when administered in an
ICU with proper monitoring of variables that affect renal func-
tion. Pending a randomized controlled trial, the use of intra-
venous colistin should be considered in severe infections
with Gram-negative bacilli when it remains the only antibiotic
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